Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tick-borne encephalitis virus (TBEV) envelope glycoprotein E is the major structural protein on the surface of the mature TBEV virion, playing a critical role in viral attachment, entry, and membrane fusion. Structurally, the E protein exists as a head-to-tail homodimer on the mature viral membrane and is composed of three distinct ectodomains: Domain I (DI), Domain II (DII, which contains the highly conserved fusion loop), and Domain III (DIII, an immunoglobulin-like domain that mediates binding to host cell receptors). Upon receptor-mediated endocytosis, the acidic environment of the host endosome triggers a dramatic, irreversible conformational rearrangement of the E protein from a dimeric to a trimeric state, exposing the fusion loop to facilitate fusion between the viral and endosomal membranes, thereby releasing the viral genome into the host cytoplasm.
As the primary surface antigen of TBEV, glycoprotein E is the principal target for both prophylactic vaccines and therapeutic interventions. Inactivated TBEV vaccines (such as FSME-IMMUN and Encepur) rely on inducing neutralizing antibodies primarily directed against the E protein to provide protective immunity. Additionally, several monoclonal antibodies (such as TBE025, which is in Phase I clinical trials, and preclinical candidates like ch14D5 and FVN-32) target specific epitopes on glycoprotein E—particularly within Domain III—to block host cell attachment or prevent the low-pH-induced membrane fusion process. Therapeutic challenges associated with targeting this protein include the potential for viral escape mutants and the theoretical risk of antibody-dependent enhancement (ADE) of infection, which requires careful epitope selection and antibody engineering.
Neutralization of viral infectivity by blocking host cell receptor binding and inhibiting low-pH-induced viral-endosomal membrane fusion; active immunization via vaccines to induce protective neutralizing antibodies.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tick-borne encephalitis virus envelope glycoprotein E (TBEV glycoprotein E).